We have new data on the experimental COVID-19 pill from Merck — called molnupiravir — that looks to help those with COVID-19 face less severe illness.
- Per Reuters, new data from Merck show that the pill reduced chances of death and hospitalization by 50%.
- The pill would be similar to Tamiflu, which is used to limit symptoms of the flu.
Now, Merck and partner Ridgeback Biotherapeutics will look to find emergency authorization for the pill sometime soon. They will need to submit applications to regulators throughout the world, like the Food and Drug Administration, before it can be used.
- “This is going to change the dialogue around how to manage COVID-19,” Robert Davis, Merck’s chief executive officer, told Reuters.
The pill will be the first oral antiviral medication for COVID-19. This would treat those who already have coronavirus — not prevent it like the vaccine.
- “Think about that,” said Duke. “You could give it to everyone in a household, or everyone in a school. Then we’re talking about a return to, maybe, normal life.”